BV heads into the back half of 2026 with a fresh analyst endorsement landing the same week shorts have been steadily rebuilding — a mild tension in an otherwise quiet story.
The most notable event this week was Oppenheimer's initiation this morning. Scott Schneeberger opened coverage with an Outperform rating and a $17 target, above the $16.68 consensus mean. That follows a meaningful pivot from JP Morgan in early May, when Andrew Steinerman upgraded the stock to Neutral from Underweight, raising his target to $14. The direction of travel from the Street has shifted positive — seven analysts now carry buy-equivalent ratings — though the more cautious desks at Morgan Stanley (Equal-Weight, $14) and Goldman Sachs (Sell, $10.50) provide a clear counter-narrative. The $16.68 consensus target implies roughly 30% upside to Tuesday's close at $12.78, a gap that reflects genuine disagreement about when the earnings recovery materialises. Valuation sits at 18.2x trailing earnings and 6.8x EV/EBITDA — neither stretched nor compellingly cheap for a business with flat revenue growth and thin margins.
Short positioning tells a quietly interesting story. Short interest has climbed roughly 22% over the past month, reaching 4.9% of the free float at 4.66 million shares — the highest it has been in the 30-day window tracked here. The week-on-week build is modest at about 3%, but the trend is consistent: shorts have added to the position on each of the last three weekly readings, suggesting deliberate rather than opportunistic accumulation. That said, the borrow market offers no squeeze fuel. Availability runs at over 2,000% — meaning shares available to borrow outnumber shares already borrowed by more than twenty to one — and cost to borrow has fallen 14% on the week to around 0.41%, a genuinely cheap level. There is no friction in the lending pool. Options positioning is equally subdued: the put/call ratio of 1.16 is almost exactly in line with its 20-day average, registering a z-score near zero, and has held in a narrow band all month.
The factor picture reinforces a mixed setup. Forward EPS momentum has turned negative on both the 30-day and 90-day windows, ranking in the bottom quintile of the universe on those measures. EPS surprise sits at a similarly weak 9th percentile. The brighter spots are a 77th-percentile reading on 12-month forward EPS year-on-year growth — suggesting analysts still model a recovery — and a 74th-percentile dividend score, though BV pays no cash dividend, so that figure likely reflects a score component unrelated to income. The ORTEX short score has crept up from 49.7 to 51.7 over the past ten days, a mild drift into bearish territory but nowhere near an extreme reading.
Institutional ownership adds some texture. KKR holds a 23% anchor stake with no reported change, while several active managers — Van Berkom, Cooke & Bieler, Harvey Partners, AllianceBernstein — reported position increases in the most recent filings. Goldman Sachs Asset Management more than doubled its position to 2.55 million shares as of April 30, notable given Goldman's sell-side desk retains a Sell rating. The insider data is stale (last recorded activity in early March), so no inference should be drawn from it about current sentiment.
With earnings next scheduled for 3 August, the immediate focus shifts to whether the Oppenheimer initiation draws further coverage and whether the slow short-build accelerates or reverses into the summer — the peer group has been mixed, with BCO down 2.4% on the week while GEO gained nearly 6%, illustrating how differentiated services names can diverge sharply on sector-level flows.
See the live data behind this article on ORTEX.
Open BV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
